Friday, November 13, 2026

Technology & Finance

5 articles

Goldman Sachs Forecasts 7-Point Big Tech ROE Drop as Global AI Spending Fails to Convert to Returns

Goldman Sachs Forecasts 7-Point Big Tech ROE Drop as Global AI Spending Fails to Convert to Returns

Goldman Sachs projects a 7 percentage point decline in Big Tech return on equity, linking the compression directly to AI capital expenditure that has not yet generated measurable revenue. The forecast, released alongside an AI spending analysis, signals an emerging global accountability phase for technology investment. Institutional investors worldwide are now reassessing premium valuations built on AI growth narratives.

LM Salvado•
Alphabet and Nvidia Quantum Advances Expose Financial Encryption Gaps Across Global Markets

Alphabet and Nvidia Quantum Advances Expose Financial Encryption Gaps Across Global Markets

Alphabet's Willow chip and Nvidia's AI-assisted quantum error correction together compress the timeline for breaking financial encryption. Banking protocols, SSL/TLS, and blockchain security face credible quantum risk before most institutions have adopted post-quantum standards. Regulators globally are expected to accelerate mandatory compliance timelines.

LM Salvado•
How a 30-Person Startup Became Hidden Infrastructure for a Third of the World's Largest Companies

How a 30-Person Startup Became Hidden Infrastructure for a Third of the World's Largest Companies

Railway, a San Francisco cloud platform founded in 2020, now underpins deployment infrastructure for 31% of Fortune 500 companies — yet operates with just 30 employees. The concentration risk this creates extends well beyond American borders, touching financial institutions, fintech platforms, and digital infrastructure across every major economy. Risk analysts have assigned the scenario a catastrophic severity rating, and the global enterprise world has largely not noticed.

ViaNews Editorial Team•
Intel, Cisco and the Global Race to Own Enterprise AI Infrastructure

Intel, Cisco and the Global Race to Own Enterprise AI Infrastructure

Two landmark moves by Intel and Cisco are reshaping the architecture of enterprise AI worldwide, arriving as central banks from Ottawa to Tokyo signal a shift in monetary conditions that could unlock a new wave of AI capital expenditure. The contest to control the silicon and networking layers of institutional AI is no longer a Silicon Valley story — it is a global infrastructure race with consequences for every major financial centre.

ViaNews Editorial Team•
The AI Infrastructure Arms Race: How CoreWeave and SoftBank's Moves Are Reshaping Global Capital Flows

The AI Infrastructure Arms Race: How CoreWeave and SoftBank's Moves Are Reshaping Global Capital Flows

Two landmark deals—CoreWeave's $1.17 billion infrastructure contract and SoftBank's reported pursuit of Marvell Technology—signal that the global AI investment cycle has matured from speculative narrative into hard-nosed capital deployment. As enterprise buyers lock in multi-year commitments and strategic acquirers target hardware intellectual property, the race to control AI's physical backbone is intensifying across the US, Asia, and Europe. Geopolitical fault lines, from US export controls to

ViaNews Editorial Team•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com